Drug Trial Radar · NCT00359021
An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).
Last checked: Nov 19, 2026Latest source record: May 16, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
503
Actual
Start
Jun 2006
Primary completion
Jan 2012
Study completion Jan 2012
Sponsor
- Lead sponsor
- Tibotec Pharmaceuticals, IrelandIndustry
- Sponsor type
- Industry
- First posted
- Aug 1, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to evaluate the long-term safety and tolerability of TMC125 200 mg twice daily as part of an antiretroviral therapy including TMC114/rtv and an investigator selected optimized background in HIV-1 infected patients who have participated in a DUET trial (TMC125-C206 or TMC125 C216) and have met the definition of virologic failure at Week 24 or later in these trials.
Conditions
- HIV-1
Interventions
TMC125Drug
200 mg twice daily until commercially available
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Participants Experiencing Adverse EventsTime frame: 1 week to 180 weeks, with a median of 62 weeks
Locations
72 sites in 14 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Little Rock, Arkansas
Site not named
Beverly Hills, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Palm Springs, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Denver, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Fort Lauderdale, Florida
Site not named
Fort Laudersale, Florida
Site not named
Miami, Florida
Site not named
North Miami Beach, Florida
Site not named
Safety Harbor, Florida
Site not named
Tampa, Florida
Site not named
Chicago, Illinois
Site not named
Boston, Massachusetts
Site not named
Camden, New Jersey
Site not named
Newark, New Jersey
Site not named
New York, New York
Site not named
The Bronx, New York
Site not named
Durham, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Austin, Texas
Site not named
Dallas, Texas
Site not named
Houston, Texas
Site not named
Longview, Texas
Site not named
Annandale, Virginia
Site not named
Seattle, Washington
Site not named
Buenos Aires, Argentina
Site not named
Córdoba, Argentina
Site not named
Neuquén, Argentina
Site not named
San Juan Bautista, Argentina
Site not named
Darlinghurst, Australia
Site not named
Antwerp, Belgium
Site not named
Liège, Belgium
Site not named
Curitiba, Brazil
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.